- Home
- PRSO vs SONN Comparison
PRSO vs SONN Comparison
Compare PRSO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- SONN
- Stock Information
- Founded
- PRSO 2008
- SONN N/A
- Country
- PRSO United States
- SONN United States
- Employees
- PRSO N/A
- SONN N/A
- Industry
- PRSO Semiconductors
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- SONN Health Care
- Exchange
- PRSO Nasdaq
- SONN Nasdaq
- Market Cap
- PRSO 4.5M
- SONN 3.8M
- IPO Year
- PRSO 2001
- SONN N/A
- Fundamental
- Price
- PRSO $0.85
- SONN $3.44
- Analyst Decision
- PRSO Strong Buy
- SONN Strong Buy
- Analyst Count
- PRSO 1
- SONN 1
- Target Price
- PRSO $3.00
- SONN $20.00
- AVG Volume (30 Days)
- PRSO 124.1K
- SONN 934.4K
- Earning Date
- PRSO 08-11-2025
- SONN 08-26-2025
- Dividend Yield
- PRSO N/A
- SONN N/A
- EPS Growth
- PRSO N/A
- SONN N/A
- EPS
- PRSO N/A
- SONN N/A
- Revenue
- PRSO $13,608,000.00
- SONN $1,000,000.00
- Revenue This Year
- PRSO $0.69
- SONN $5,376.22
- Revenue Next Year
- PRSO $35.21
- SONN N/A
- P/E Ratio
- PRSO N/A
- SONN N/A
- Revenue Growth
- PRSO 1.80
- SONN 978.39
- 52 Week Low
- PRSO $0.52
- SONN $1.08
- 52 Week High
- PRSO $2.34
- SONN $19.30
- Technical
- Relative Strength Index (RSI)
- PRSO 43.33
- SONN 48.94
- Support Level
- PRSO $0.80
- SONN $2.80
- Resistance Level
- PRSO $0.93
- SONN $4.29
- Average True Range (ATR)
- PRSO 0.05
- SONN 0.55
- MACD
- PRSO 0.01
- SONN -0.02
- Stochastic Oscillator
- PRSO 54.46
- SONN 58.56
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.